Terns Pharmaceuticals, a biopharma company focused on discovering and developing molecularly targeted, oral, small-molecule drugs for the treatment of NASH and cancer, has raised $80m through a Series B financing round.
Terns president and CEO Weidong Zhong said: “Since we launched the company a short time ago, we have been working diligently to advance our key programs and continue executing on our strategy to bring innovative therapeutics to underserved patients globally, and with this financing we are well positioned to continue to execute on that mission.
“We are excited about the progress we’ve made on our clinical and preclinical programs. Our lead programs TERN-101 and TERN-201 are on track to enter the clinic in the first half of 2019 and additional NASH programs are advancing rapidly towards preclinical development.
“The progress so far has put us one step closer to our goal of discovering effective and safe combination therapies for patients with NASH and liver fibrosis. We are grateful for the confidence and enthusiasm coming from our new and existing investors.”
Vivo Capital managing partner and Co-CEO Shan Fu said: “Terns leverages a combination of expertise in disease biology, medicinal chemistry, and extensive clinical development capabilities to build its high-quality and diverse pipeline for the treatment of NASH, offering an incredible opportunity to bring potentially promising new therapies to patients.
“We are excited to be co-leading a great group of investors and are believers in the novel approach Terns is taking. Vivo has substantial investment experience in the development of therapeutics for NASH. We believe that we will add value to the company in terms of its future development.”
OrbiMed managing partner Carl Gordon said: “Their approach of adopting global or region-specific development strategies for advancing new clinical-stage therapeutics is unique, and Terns has made tremendous progress since they recently launched.
“This gives us great confidence in their ability to successfully sustain that forward trajectory.”
The financing was led by new investors Vivo Capital and OrbiMed, joined by new investor Decheng Capital; existing investor Lilly Asia Ventures also participated to provide continuous support.
Source: Company Press Release